DOP2017000159A - Sal de tosilato de n-[3-[(4ar,7as)-2-amino-6-(5-fluoropirimidina-2-il)-4,4a,5,7-tetrahidropirrolo[3,4-d][1,3]tiazina-7a-il]-4-fluoro-fenil]-5-metoxi-pirazina-2-carboxamida - Google Patents

Sal de tosilato de n-[3-[(4ar,7as)-2-amino-6-(5-fluoropirimidina-2-il)-4,4a,5,7-tetrahidropirrolo[3,4-d][1,3]tiazina-7a-il]-4-fluoro-fenil]-5-metoxi-pirazina-2-carboxamida

Info

Publication number
DOP2017000159A
DOP2017000159A DO2017000159A DO2017000159A DOP2017000159A DO P2017000159 A DOP2017000159 A DO P2017000159A DO 2017000159 A DO2017000159 A DO 2017000159A DO 2017000159 A DO2017000159 A DO 2017000159A DO P2017000159 A DOP2017000159 A DO P2017000159A
Authority
DO
Dominican Republic
Prior art keywords
fluoro
phenyl
amino
tiazina
tetrahydropirrolo
Prior art date
Application number
DO2017000159A
Other languages
English (en)
Inventor
Andrew Coates David
Daniel Wolfangel Craig
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of DOP2017000159A publication Critical patent/DOP2017000159A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La invención presente invención se refiere a una sal de tosilato de N-[3-[(4aR,7aS)-2-amino-6-(5-fluoropirimidin-2-il)-4,4a,5,7-tetrahidropirrolo[3,4-d][1,3]tiazin-7a-il]-4-fluoro-fenil]-5-metoxi-pirazina-2-carboxamida.
DO2017000159A 2015-01-30 2017-07-03 Sal de tosilato de n-[3-[(4ar,7as)-2-amino-6-(5-fluoropirimidina-2-il)-4,4a,5,7-tetrahidropirrolo[3,4-d][1,3]tiazina-7a-il]-4-fluoro-fenil]-5-metoxi-pirazina-2-carboxamida DOP2017000159A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562109733P 2015-01-30 2015-01-30

Publications (1)

Publication Number Publication Date
DOP2017000159A true DOP2017000159A (es) 2017-07-31

Family

ID=55275232

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2017000159A DOP2017000159A (es) 2015-01-30 2017-07-03 Sal de tosilato de n-[3-[(4ar,7as)-2-amino-6-(5-fluoropirimidina-2-il)-4,4a,5,7-tetrahidropirrolo[3,4-d][1,3]tiazina-7a-il]-4-fluoro-fenil]-5-metoxi-pirazina-2-carboxamida

Country Status (41)

Country Link
US (1) US10080758B2 (es)
EP (1) EP3250575B1 (es)
JP (2) JP6723250B2 (es)
KR (1) KR101950129B1 (es)
CN (1) CN107108657B (es)
AR (1) AR103406A1 (es)
AU (1) AU2016211827B2 (es)
BR (1) BR112017012149A2 (es)
CA (1) CA2969475C (es)
CL (1) CL2017001899A1 (es)
CO (1) CO2017007810A2 (es)
CR (1) CR20170287A (es)
CY (1) CY1122548T1 (es)
DK (1) DK3250575T3 (es)
DO (1) DOP2017000159A (es)
EA (1) EA031330B1 (es)
EC (1) ECSP17048768A (es)
ES (1) ES2768782T3 (es)
GT (1) GT201700166A (es)
HR (1) HRP20192240T1 (es)
HU (1) HUE048029T2 (es)
IL (1) IL252754A0 (es)
LT (1) LT3250575T (es)
MA (1) MA41420B1 (es)
MD (1) MD3250575T2 (es)
ME (1) ME03581B (es)
MX (1) MX2017009713A (es)
NZ (1) NZ732381A (es)
PE (1) PE20171333A1 (es)
PH (1) PH12017501356A1 (es)
PL (1) PL3250575T3 (es)
PT (1) PT3250575T (es)
RS (1) RS59730B1 (es)
SG (1) SG11201706038PA (es)
SI (1) SI3250575T1 (es)
SV (1) SV2017005478A (es)
TN (1) TN2017000332A1 (es)
TW (1) TWI574969B (es)
UA (1) UA119581C2 (es)
WO (1) WO2016122968A1 (es)
ZA (1) ZA201703937B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR103406A1 (es) * 2015-01-30 2017-05-10 Lilly Co Eli Sal de tosilato
WO2019094608A1 (en) 2017-11-08 2019-05-16 Denali Therapeutics Inc. Anti-bace1 antibodies and methods of use thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT401651B (de) * 1994-06-14 1996-11-25 Biochemie Gmbh 7-(2-(2-aminothiazol-4-yl)-2-(z)- hydroximinoacetamido)-3-n,n- dimethylcarbamoyloxymethyl-3-cephem-4-
NZ585671A (en) * 2007-12-07 2012-06-29 Pfizer Tosylate salt of trans-n-isobutyl-3-fluoro-3- [3-fluoro-4- (pyrrolidin-1-yl-methyl) -phenyl] cyclobut anecarboxamide
US8158620B2 (en) * 2008-01-18 2012-04-17 Eisai R&D Management Co., Ltd. Fused aminodihydrothiazine derivatives
TWI593692B (zh) * 2013-03-12 2017-08-01 美國禮來大藥廠 四氫吡咯并噻嗪化合物
TWI570127B (zh) * 2014-09-15 2017-02-11 美國禮來大藥廠 結晶型N-[3-[(4aR,7aS)-2-胺基-6-(5-氟嘧啶-2-基)-4,4a,5,7-四氫吡咯并[3,4-d][1,3]噻嗪-7a-基]-4-氟-苯基]-5-甲氧基-吡嗪-2-甲醯胺、其用途及醫藥組合物
AR103406A1 (es) * 2015-01-30 2017-05-10 Lilly Co Eli Sal de tosilato

Also Published As

Publication number Publication date
RS59730B1 (sr) 2020-02-28
MX2017009713A (es) 2017-11-17
DK3250575T3 (da) 2020-01-20
US20170368071A1 (en) 2017-12-28
EP3250575B1 (en) 2019-11-20
ZA201703937B (en) 2019-01-30
CL2017001899A1 (es) 2018-03-23
JP2019142902A (ja) 2019-08-29
SG11201706038PA (en) 2017-08-30
SI3250575T1 (sl) 2019-12-31
EP3250575A1 (en) 2017-12-06
ECSP17048768A (es) 2017-11-30
CA2969475C (en) 2019-06-18
GT201700166A (es) 2018-11-23
SV2017005478A (es) 2018-02-09
HUE048029T2 (hu) 2020-05-28
TN2017000332A1 (en) 2019-01-16
ES2768782T3 (es) 2020-06-23
IL252754A0 (en) 2017-08-31
PH12017501356A1 (en) 2017-12-11
KR20170097782A (ko) 2017-08-28
EA031330B1 (ru) 2018-12-28
CA2969475A1 (en) 2016-08-04
PE20171333A1 (es) 2017-09-13
MA41420B1 (fr) 2020-02-28
BR112017012149A2 (pt) 2018-01-02
KR101950129B1 (ko) 2019-02-19
HRP20192240T1 (hr) 2020-03-06
ME03581B (me) 2020-07-20
JP6723250B2 (ja) 2020-07-15
AR103406A1 (es) 2017-05-10
CN107108657A (zh) 2017-08-29
NZ732381A (en) 2018-05-25
EA201791229A1 (ru) 2017-11-30
CN107108657B (zh) 2021-10-08
LT3250575T (lt) 2020-02-10
US10080758B2 (en) 2018-09-25
CO2017007810A2 (es) 2017-10-20
PT3250575T (pt) 2020-01-16
JP2018503666A (ja) 2018-02-08
AU2016211827A1 (en) 2017-06-22
TWI574969B (zh) 2017-03-21
CY1122548T1 (el) 2021-01-27
WO2016122968A1 (en) 2016-08-04
TW201636354A (zh) 2016-10-16
MD3250575T2 (ro) 2020-03-31
PL3250575T3 (pl) 2020-06-01
AU2016211827B2 (en) 2018-04-26
UA119581C2 (uk) 2019-07-10
CR20170287A (es) 2017-07-20

Similar Documents

Publication Publication Date Title
MA47123A (fr) Dérivés de benzooxazole en tant qu'mmunomodulateurs
MA42990A (fr) Composés utiles en tant qu'immunomodulateurs
MA40587A (fr) Composés d'aminopyrimidinyle en tant qu'inhibiteurs de jak
BR112016026942A2 (pt) geração de visualizações de direção curva por curva.
MA48803A (fr) Cycles 6-5 fusionnés utilisés en tant qu'inhibiteurs de c5a
MA41542A (fr) Nouveaux dérivés de n-acyl-arylsulfonamide utilisés en tant qu'inhibiteurs d'aminoacyl-arnt synthétase
MX2016014765A (es) Incremento del rendimiento utilizando soforolipidos.
DK3397621T3 (da) Fremgangsmåde til fremstilling af 1,1,3-trioxo-1,2-benzothiazol-6-carboxamid
CO2017007810A2 (es) Sal de tosilato de n-[3-[4ar,7as)-2-amino-6-(5-fluoropirimidin-2-il)-4,4a,5,7-tetrahidropirrolo[3,4-d][1,3]tiazin-7a-il-4-fluoro-fenil]-5-metoxi-pirazina-2-carboxamida
MA41174A (fr) Dérivés d'imidazopyridazine utilisés en tant qu'inhibiteurs de pi3kbeta
CL2017000645A1 (es) Síntesis de ent-progesterona e intermediarios de la misma
DK3397620T3 (da) Fremgangsmåde til fremstilling af 1,1,3-Trioxo-1,2-benzothiazol-6-carboxamid
CO2017001927A2 (es) Formas cristalinas de n-[3-[(4ar,7as)-2-amino-6-(5- fluoropirimidin-2-il)-4,4a,5,7-tetrahidropirrolo[3,4-d][1,3]tiazin-7a-il]-4-fluoro-fenil]-5-metoxi-pirazin-2-carboxamida como inhibidores de bace
BR112019002828A2 (pt) método de preparação de derivados de estireno substituído
DOP2017000016A (es) Nueva sal de disoproxilo de tenofovir
MA45184A (fr) Procédé de préparation de l'éluxadoline .
TH182870B (th) เกลือทอซิเลทของ n-[3-[(4ar,7as)-2-อะมิโน-6-(5-ฟลูออโรพิริมิดิน-2-อิล)-4,4a,5,7-เททระไฮโดรพิร์โรโล[3,4-d][1,3]ไธอะซิน-7a-อิล]-4-ฟลูออโร-เฟนิล]-5-เมธอกซิ-ไพแรซีน-2-คาร์บอกแซมีด
TH182897B (th) อุปกรณ์สำหรับยึดแกนกระดุม
TH183362B (th) "สิ่งเข้มข้นปรุงแต่งรสชาติที่มีรูปร่าง"
TH1601005811B (th) โครงสร้างส่วนประดับด้านหน้าของรถจักรยานยนต์
UA93238U (uk) Комплексний препарат "глуцисаргін"
TH1601000029A (th) วงแหวนคาร์บอกซาไมด์ที่มีสมาชิก 4 อะตอมที่ถูกใช้เป็นสารกำจัดไส้เดือนฝอย